Academic Journal
Q1American Journal of Nephrology
About American Journal of Nephrology
About American Journal of Nephrology
American Journal of Nephrology is a peer-reviewed scholarly journal published by S. Karger AG (Switzerland). It focuses on Q1. Publication coverage spans 1981-2026.
Key indicators: ISSN 1421-9670, 0250-8095; H-index 109.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (109): Exceptionally high — 109 articles have each been cited at least 109 times. This indicates deep, sustained influence in the field.
Publishing in American Journal of Nephrology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of American Journal of Nephrology?
1421-9670, 0250-8095.
Who publishes American Journal of Nephrology?
S. Karger AG.
What are American Journal of Nephrology's metrics?
H-index 109.
Where do I submit to American Journal of Nephrology?
Via the official website.
Is American Journal of Nephrology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Dialysis and Renal Disease Management; Chronic Kidney Disease and Diabetes; Renal Diseases and Glomerulopathies; Acute Kidney Injury Research; Parathyroid Disorders and Treatments; Diverse Scientific and Economic Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Deciphering the Molecular and Cellular Landscape of Early Diabetic Nephropathy through Single-Cell RNA Sequencing and Protein-Protein Interaction Networks
Li Qin, Yan Liang, Liying Xuan, Ruibin He et al.
2026-10-16 · DOI: 10.1159/ajn/ablag024Fluid Intake and Kidney Function: A Systematic Review and Dose–Response Meta-analysis
Jia-Jin Chen, Tao Han Lee, Cheng-Chia Lee, Ming-Jen Chan et al.
2026-10-16 · DOI: 10.1159/ajn/ablag027Urinary biomarkers at hospital admission and community-acquired acute kidney injury: A prospective cohort
Farid Samaan, Flávia Barros de Azevedo, Dirce Maria Trevisan Zanetta, Luis Yu et al.
2026-10-16 · DOI: 10.1159/ajn/ablag026Tubuloreticular Inclusions in Kidney Tissues of Patients with Lupus Nephritis: An Ultrastructural Biomarker of Type I Interferon-Driven Disease Activity
Tianyuan Wei, Jiahui Zhang, Fan Yang, Changming Zhang et al.
2026-10-15 · DOI: 10.1159/ajn/ablag021Risk of kidney failure in biopsy-verified kidney disease type in type 2 diabetes: A registry-based longitudinal cohort study
Karina Haar, Martin Baek Blond, Frederik Persson, Iain Bressendorff et al.
2026-10-15 · DOI: 10.1159/ajn/ablag016RealxWorld Effectiveness of Targeted-Release Budesonide in IgA Nephropathy with Near-Universal SGLT2 Inhibitor Use
Thomas McDonnell, William R. Marshall, Sharmilee Rengarajan, Jude Allen et al.
2026-10-15 · DOI: 10.1159/ajn/ablag015Integrated Analysis of the aKlotho–FGF23–FGFR Genetic Axis Reveals Determinants of Cardiovascular Risk in Chronic Kidney Disease
Vanessa Nobles, Virginia Díaz-Acevedo, Laura González-Rodríguez, Bárbara Cancho et al.
2026-10-14 · DOI: 10.1159/ajn/ablag018Response to the Letter to the Editor Entitled “Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy: Caution in effect Attribution”
Huixian Li, Wanhong Lu
2026-10-12 · DOI: 10.1159/ajn/ablag028The Solitary Functioning Kidney: From Pathophysiology to Long-Term Management
Ranhao Li, Hongxia Mai, Wenjun Zhang
2026-10-10 · DOI: 10.1159/ajn/ablag029Mesenchymal stromal cell derived membrane particles improve metabolic activity and functional performance during porcine kidney normothermic machine perfusion
Shengbing Li, Yitian Fang, Robert C. Minnee, Ron de Bruin et al.
2026-10-10 · DOI: 10.1159/ajn/ablag010Association of Hemoglobin Levels with Progression to End-stage Kidney Disease in IgA Nephropathy: A Sex-Specific Analysis
Ji-Eun Yoo, Kyu Yeun Kim, Man-Hoon Han, Yong-Jin Kim et al.
2026-10-10 · DOI: 10.1159/ajn/ablag012The Cardiorenal Protective Effects of Low-dose Tolvaptan in Peritoneal Dialysis Patients with Volume Overload
Xinyang Li, Panpan Chao, Chongyu Zhang, Wenpeng Cui et al.
2026-10-08 · DOI: 10.1159/ajn/ablag013A new beating heart model of cardiopulmonary bypass-induced acute kidney injury demonstrates heme protein toxicity and ferroptosis
Kathryn Smedlund, Dulat Bekbolsynov, Mustafa Azizi, Apurva Lad et al.
2026-09-29 · DOI: 10.1159/ajn/ablag022Viewpoint: Microvascular Failure at the Cardiorenal Crossroads: Rethinking Congestion in HFpEF and CKD
Carmine Zoccali, Francesca Mallamaci, Raffaele De Caterina
2026-09-17 · DOI: 10.1159/ajn/ablag014Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes
Joel Shah, Eder Luna Ceron, Fernanda Payan-Schober, Lisa Aimee Hechanova et al.
2026-09-09 · DOI: 10.1159/ajn/ablag011Additive Obinutuzumab in Rituximab-refractory Membraneous Nephropathy: Caution in Effect Attribution
Emre Cankaya, Burak Aslum, Ezgi Çoskun Yenigun
2026-09-05 · DOI: 10.1159/ajn/ablag009Monitoring Long-Term Tacrolimus Exposure: Metrics, Trajectories, and Associations with Outcomes after Kidney Transplantation in the Wisconsin Allograft Recipient Database
Zhongyu Yuan, Sandesh Parajuli, Didier Mandelbrot, Brad C. Astor et al.
2026-09-02 · DOI: 10.1159/000552040Barriers to Person-Centered CKD Care: A Qualitative Study of Multidisciplinary Nephrology Clinicians
In-Gu Kang, JoAnn S. Oliver, Nayoung Kim, Ashley Abawi et al.
2026-09-01 · DOI: 10.1159/ajn/ablag007Adynamic Bone Disease in Chronic Kidney Disease: From PTH Suppression–Driven Remodeling Phenotype to Osteoanabolic Therapy
Kuo-Cheng Lu, Yi-Chou Hou, Chia-Chao Wu, Te-Chao Fang et al.
2026-08-31 · DOI: 10.1159/ajn/ablag003Hyperglycemia and Alteration in Sphingolipids Are Early Mediators of Diabetic Kidney Disease: Role of Elongase 1
Waleed O. Twal, Peggi M. Angel, Kristi L. Helke, Alexander Awgulewitsch et al.
2026-08-28 · DOI: 10.1159/000552867Reviews
Community Reviews
Version History
October 9, 2026 at 8:10 pm
September 25, 2026